CIK 0001534120
- Non-accelerated filer
- Smaller reporting company
Avalo Therapeutics, Inc.
Sign in to watch- Ticker
- AVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 450705648
- Phone
- +1 410-522-8707
- Business address
- 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE, PA, 19087
- Former names
- Cerecor Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $395,474
- in 3 filings, $395K under 10b5-1 plans
Net −$395,474. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-10 | Wilkins H Jeffrey Chief Medical Officer | Purchase | +912 | $2.28 | $2K | 27,002 |
| 2021-05-18 | ARMISTICE CAPITAL, LLC Director | Purchase | +22,000 | $2.33 | $51K | 39,100,000 |
| 2021-05-18 | ARMISTICE CAPITAL, LLC Director | Purchase | +0 | 39,100,000 | ||
| 2021-05-17 | ARMISTICE CAPITAL, LLC Director | Purchase | +30,000 | $2.20 | $66K | 39,078,000 |
| 2021-05-17 | ARMISTICE CAPITAL, LLC Director | Purchase | +0 | 39,078,000 | ||
| 2021-05-14 | ARMISTICE CAPITAL, LLC Director | Purchase | +128,000 | $2.15 | $275K | 39,048,000 |
| 2021-05-14 | ARMISTICE CAPITAL, LLC Director | Purchase | +0 | 39,048,000 | ||
| 2021-04-15 | ARMISTICE CAPITAL, LLC Director | Conversion | +6,285,715 | $2.00 | $12.6M | 38,920,000 |
| 2021-04-15 | ARMISTICE CAPITAL, LLC Director | Conversion | +0 | 38,920,000 | ||
| 2021-04-15 | ARMISTICE CAPITAL, LLC Director | Conversion · SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK | −1,257,143 | 0 | ||
| 2021-04-15 | ARMISTICE CAPITAL, LLC Director | Conversion · SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK | −0 | 0 | ||
| 2021-04-01 | COLA MICHAEL F Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +70,881 | 70,881 | ||
| 2021-03-31 | Gutry Phil Director | Grant or award · Stock Option (Right to Buy) | +3,783 | 3,783 | ||
| 2021-03-31 | Miller Joseph M Director | Grant or award · Stock Option (Right to Buy) | +5,564 | 5,564 | ||
| 2021-03-31 | Persson Magnus Director | Grant or award · Stock Option (Right to Buy) | +4,799 | 4,799 | ||
| 2021-03-31 | Bruhn Suzanne Louise Director | Grant or award · Stock Option (Right to Buy) | +4,173 | 4,173 | ||
| 2021-03-31 | KAPLAN GILLA Director | Grant or award · Stock Option (Right to Buy) | +7,650 | 7,650 | ||
| 2021-03-01 | Greenway Schond L. CFO & Treasurer | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2021-01-26 | Sullivan Christopher Ryan Interim CFO | Grant or award · Stock Option (Right to Buy) | +110,000 | 110,000 | ||
| 2021-01-26 | COLA MICHAEL F Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +850,000 | 850,000 |
Page 18 of 25 · 500 trades